Free shipping on all orders over $ 500

Necitumumab

Cat. No. M25443

All AbMole products are for research use only, cannot be used for human consumption.

Necitumumab Structure

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Necitumumab is a second-generation fully humanized immunoglobulin G1 (IgG1), epidermal growth factor (EGFR) receptor monoclonal antibody that specifically blocks the ligand binding site of EGFR. 

Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR signaling pathway, inhibiting tumor growth, angiogenesis, and anti-apoptotic mechanisms. Necitumumab inhibited the interaction of EGF and EGFR with a concentration that inhibits binding by 50 % of approximately 0.9 nM (0.13 mg/L) and demonstrated antitumor activity during in vivo experiments associated with trough plasma concentrations of approximately 40 mg/L. 

Necitumumab effective half-life was estimated to approximately 2 weeks, and steady state was achieved within three to four cycles of treatment.

Chemical Information
CAS Number 906805-06-9
Storage -20°C or -80°C
References

[1] No authors listed. Necitumumab

[2] Asunción Díaz-Serrano, et al. Future Oncol. Necitumumab for the treatment of advanced non-small-cell lung cancer

[3] No authors listed. Necitumumab

[4] Karly P Garnock-Jones. Drugs. Necitumumab: First Global Approval

[5] Nick Thatcher, et al. Lancet Oncol. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Related EGFR/HER2 Products
Sevabertinib

Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.

BPIQ-I

BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor..

HKI-357 

HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively.

SJF-1528 

SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells.

CH7233163 

CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S.

  Catalog
Abmole Inhibitor Catalog




Keywords: Necitumumab supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.